RxDoctor Payments Data

Michael Diringer

Critical Care Medicine · Saint Louis, MONPI 1881625390

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $1,900 of the $2,487 with a category attached, or 76.4%. Pfizer accounts for 76.4% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $1,970 and has fallen 95.4% since, to $91 in 2021.

$2,487in general payments, 2019–2025

Across 4 payments — averaging $621.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$2K
  • AstraZeneca$427
  • ZOLL Circulation Inc$91
  • Bard Access Systems, Inc.$70
$525,023in research payments, 2019–2025

Across 15 payments — averaging $35,002 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • C. R. Bard, Inc. & Subsidiaries$498K
  • Biogen$24K
  • Bard Peripheral Vascular, Inc.$4K

What the payments were for

  • Consulting fees$42717%
  • Speaking & faculty fees$1,90076%
  • Food & beverage$1616%

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,487 in reported general payments places this provider in the 85th percentile of 208 critical care medicine providers in Missouri.

See all critical care medicine providers in Missouri →

Other critical care medicine in Saint Louis

See the full list for Missouri →

Where these figures come from

Is this you, or does something look wrong? →